An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

• Status: Completed
• Trial end date: 2020-07-24
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Iodine; Sorafenib

Criteria

Inclusion Criteria:

• Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and poorly differentiated carcinoma)

• DTC refractory to RAI

• Radiological progression and preferably according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

• No symptoms due to DTC

• >/=1cm diameter of lesion confirmed by radiological exam

• Life expectancy of at least 6 months

Exclusion Criteria:

• Plan to be treated according to a clinical trial protocol for intervention including a locoregional therapy or systemic therapy

• Previous treatment with MKIs for advanced disease

• Hospice patients